西甲硅油治疗肠易激综合征患者对胃肠激素、肠道菌群及NLRP3炎性小体介导的炎性过程的影响

doi:10.3969/j.issn.1006-5725.2024.02.019

Abstract

Abstract:

Objective To explore the effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NOD?like receptor protein 3 （NLRP3） inflammasome in patients with irritable bowel syndrome （IBS）. Methods A total of 120 patients with IBS admitted to the hospital were prospectively enrolled as the research objects between January 1， 2021 and December 31， 2022， and they were randomly divided into control group （60 cases） and treatment group （60 cases）. The control group was treated with compound eosinophil?Lactobacillus， while treatment group was additionally treated with simethicone. The curative effect after treatment， scores of gastrointestinal symptom rating scale （GSRS）， levels of somatostatin （SS）， vasoactive intestinal peptide （VIP）， NLRP3 inflammasome， interleukin?8 （IL?8） and interleukin?1β （IL?1β）， counts of intestinal floras before and after treatment， and safety during treatment were compared between the two groups. Results After treatment， total response rate of treatment group was higher than that of control group （91.67% vs. 76.67%， P < 0.05）. After treatment， GSRS scores in both groups were decreased， which were lower in treatment group than control group （P < 0.05）. After treatment， levels of SS and VIP in both groups were decreased， which were lower in treatment group than control group （P < 0.05）. After treatment， counts of eosinophil?Lactobacillus and Bifidobacteria were increased in both groups， the difference was statistically significant （P < 0.05）， but there was no significant difference in counts of intestinal floras between the two groups （P > 0.05）. After treatment， levels of NLRP3 inflammasome， IL?8 and IL?1β were decreased in both groups， the difference was statistically significant （P < 0.05）， but there was no significant difference between the two groups （P > 0.05）. During treatment， there was no significant difference in side effects between the two groups （P > 0.05）. Conclusion Simethicone can significantly improve response rate of treatment， improve gastrointestinal symptoms and gastrointestinal hormones in IBS patients， which has no significant effects on intestinal floras and inflammatory process mediated by NLRP3 inflammasome， with good safety.

Key words: simethicone, irritable bowel syndrome, gastrointestinal hormone, NOD?like receptor protein 3 inflammasome

CLC Number:

R574.4

Xin LING,Jiaping QIAN,Dongtao SHI,Jun YANG,Peili FEI. Effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NLRP3 inflammasome in patients with irritable bowel syndrome[J]. The Journal of Practical Medicine, 2024, 40(2): 237-241.

Figures/Tables 7

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Tab.6

Tab.7

References 24

1	GOODOORY V C， NG C E， BLACK C J， et al. Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome［J］. Aliment Pharmacol Ther， 2022， 55（10）：1311-1319. doi:10.1111/apt.16816 doi: 10.1111/apt.16816
2	BHATT R R， GUPTA A， LABUS J S， et al. A neuropsychosocial signature predicts longitudinal symptom changes in women with irritable bowel syndrome［J］. Mol Psychiatry， 2022， 27（3）：1774-1791. doi:10.1038/s41380-021-01375-9 doi: 10.1038/s41380-021-01375-9
3	CAMILLERI M， CARLSON P， BOUSABA J， et al. Comparison of biochemical， microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea［J］. Gut， 2023， 72（1）：54-65. doi:10.1136/gutjnl-2022-327471 doi: 10.1136/gutjnl-2022-327471
4	YANG H， LIU X， PENG W， et al. Lipi Guben decoction in treating diarrheal irritable bowel syndrome： A study protocol for a randomized controlled trial［J］. Medicine （Baltimore）， 2021， 100（3）：e23887-e23887. doi:10.1097/md.0000000000023887 doi: 10.1097/md.0000000000023887
5	宋小平，陈显韬，敬秀平. 加味逍遥散联合双歧杆菌三联活菌胶囊治疗肠易激综合征的临床疗效及对肠道微生态功能的影响［J］. 解放军医药杂志， 2020， 32（2）：84-87，92. doi:10.3969/j.issn.2095-140X.2020.02.021 doi: 10.3969/j.issn.2095-140X.2020.02.021
6	胡先平，马锐. 复方嗜酸乳杆菌联合匹维溴铵治疗腹泻型肠易激综合征效果观察［J］. 现代消化及介入诊疗， 2018， 23（3）：359-361. doi:10.3969/j.issn.1672-2159.2018.03.032 doi: 10.3969/j.issn.1672-2159.2018.03.032
7	谭林，杨培. 5-HT4受体激动剂联合西甲硅油治疗非溃疡性消化不良的效果观察［J］. 广东医学， 2021， 42（3）：331-334.
8	DROSSMAN D A. The functional gastrointestinal disorders and the Rome III process［J］. Gastroenterology， 2006， 130（5）：1377-1390. doi:10.1053/j.gastro.2006.03.008 doi: 10.1053/j.gastro.2006.03.008
9	SINGH P， NEE J. Role of Diet in Diarrhea-predominant Irritable Bowel Syndrome［J］. J Clin Gastroenterol， 2021， 55（1）：25-29. doi:10.1097/mcg.0000000000001445 doi: 10.1097/mcg.0000000000001445
10	PORCELLI P， DE CARNE M， TODARELLO O. Prediction of treatment outcome of patients with functional gastrointestinal disorders by the diagnostic criteria for psychosomatic research［J］. Psychother Psychosom， 2004， 73（3）：166-173. doi:10.1159/000076454 doi: 10.1159/000076454
11	ZHANG C Y， YAO X， SUN G， et al. Close association between abnormal expressed enzymes of energy metabolism and diarrhea-predominant irritable bowel syndrome［J］. Chin Med J （Engl）， 2019， 132（2）：135-144. doi:10.1097/cm9.0000000000000003 doi: 10.1097/cm9.0000000000000003
12	KOLOSKI N A， JONES M， WALKER M M， et al. Sleep disturbances in the irritable bowel syndrome and functional dyspepsia are independent of psychological distress： a population-based study of 1322 Australians［J］. Aliment Pharmacol Ther， 2021， 54（5）：627-636. doi:10.1111/apt.16500 doi: 10.1111/apt.16500
13	LÖVDAHL J， TÖRNBLOM H， RINGSTRÖM G， et al. Randomised clinical trial： individual versus group hypnotherapy for irritable bowel syndrome［J］. Aliment Pharmacol Ther， 2022， 55（12）：1501-1511. doi:10.1111/apt.16934 doi: 10.1111/apt.16934
14	CHEY W D， KEEFER L， WHELAN K， et al. Behavioral and Diet Therapies in Integrated Care for Patients With Irritable Bowel Syndrome［J］. Gastroenterology， 2021， 160（1）：47-62. doi:10.1053/j.gastro.2020.06.099 doi: 10.1053/j.gastro.2020.06.099
15	SPERBER A D. Epidemiology and Burden of Irritable Bowel Syndrome： An International Perspective［J］. Gastroenterol Clin North Am， 2021， 50（3）：489-503. doi:10.1016/j.gtc.2021.04.001 doi: 10.1016/j.gtc.2021.04.001
16	谢宁，李曼，唐鄂. 胆舒胶囊联合酪酸梭菌活菌片治疗肠易激综合征的临床疗效［J］. 中国新药与临床杂志， 2018， 37（11）：651-654.
17	王少鑫，崔立红，弓三东，等. 西甲硅油联合枯草杆菌肠球菌对肠易激综合征的疗效观察［J］. 现代生物医学进展， 2017， 17（6）：1102-1105.
18	HOLVOET T， JOOSSENS M， VÁZQUEZ-CASTELLANOS J F， et al. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating： Short- and Long-term Results From a Placebo-Controlled Randomized Trial［J］. Gastroenterology， 2021， 160（1）：145-157. doi:10.1053/j.gastro.2020.07.013 doi: 10.1053/j.gastro.2020.07.013
19	王赛珊. 复方嗜酸乳杆菌片联合乳果糖对便秘型肠易激综合征患者肠道菌群的影响［J］. 重庆医学， 2022， 51（1）：267-269.
20	王洋，黎晓琴，史思文，等. 聚乙二醇联合西甲硅油对结肠镜检查患者Boston肠道准备量表评分及耐受度的影响［J］. 中国综合临床， 2021， 37（5）：411-415. doi:10.3760/cma.j.cn101721-20201117-00050 doi: 10.3760/cma.j.cn101721-20201117-00050
21	郝芙蓉. 子宫肌瘤术后胃肠功能紊乱经平胃散、西甲硅油联合治疗的效果分析［J］. 现代消化及介入诊疗， 2019， 24（6）：629-631. doi:10.3969/j.issn.1672-2159.2019.06.016 doi: 10.3969/j.issn.1672-2159.2019.06.016
22	王波，林建霞，王鹏. 枯草杆菌肠球菌二联活菌对便秘型肠易激综合征患者胃肠激素及IL-18、IL-23、TNF-α水平的影响［J］. 贵州医药， 2021， 45（6）：871-872.
23	赵峰，刘露，孙颖，等. Hp感染对慢性胃炎患者胃黏膜病变和miR-22与NLRP3炎症小体和肠道菌群的影响［J］. 中华医院感染学杂志， 2022， 32（19）：2940-2944.
24	韩棉梅，马军，宋雨鸿，等. 结肠灵通过调节NLRP3炎性小体活化对感染后肠易激综合征大鼠内脏敏感性的机制研究［J］. 胃肠病学和肝病学杂志， 2020， 29（10）：1145-1150. doi:10.3969/j.issn.1006-5709.2020.10.014 doi: 10.3969/j.issn.1006-5709.2020.10.014

项目	观察组（n = 60）	对照组（n = 60）	χ²/t值	P值
男性/女性（例）	29/31	25/35	0.539	0.463
年龄（x ± s，岁）	45.68 ± 7.39	46.11 ± 7.74	0.311	0.756
病程（x ± s，月）	13.47 ± 2.31	13.15 ± 2.53	0.724	0.471
疾病类型（例）			0.645	0.886
腹胀型	26	28
便秘型	21	17
混合型	5	6
不定型	8	9

项目	观察组（n = 60）	对照组（n = 60）	χ²值	P值
显效	23（38.33）	17（28.33）
有效	32（53.33）	29（48.33）
无效	5（8.33）	14（23.33）
总有效率（%）	91.67	76.67	5.065	0.024

时间	对照组（n = 60）	观察组（n = 60）	t值	P值
治疗前	2.26 ± 0.44	2.33 ± 0.36	0.954	0.342
治疗后	1.05 ± 0.12	1.21 ± 0.28	4.068	< 0.001
t值	20.551	19.022
P值	< 0.001	<0 .001

项目	观察组（n = 60）	对照组（n = 60）	t值	P值
SS（ng/mL）
治疗前	53.84 ± 7.63	52.36 ± 7.49	1.072	0.286
治疗后	23.61 ± 4.68	41.55 ± 6.30	17.707	< 0.001
t值	26.160	8.555
P值	< 0.001	< 0.001
VIP（pg/mL）
治疗前	304.16 ± 16.24	302.74 ± 17.56	0.460	0.646
治疗后	214.34 ± 10.87	261.91 ± 12.31	22.437	< 0.001
t值	35.602	14.748
P值	< 0.001	< 0.001

项目	观察组（n = 60）	对照组（n = 60）	t值	P值
嗜酸乳杆菌
治疗前	3.85 ± 1.21	4.09 ± 1.14	1.118	0.266
治疗后	5.15 ± 1.43	5.22 ± 1.28	0.283	0.778
t值	5.376	5.107
P值	< 0.001	< 0.001
大肠埃希菌
治疗前	5.86 ± 1.52	5.76 ± 1.21	0.399	0.691
治疗后	6.33 ± 1.29	6.17 ± 1.47	0.634	0.528
t值	1.826	1.668
P值	0.070	0.098
粪链球菌
治疗前	4.21 ± 1.36	4.14 ± 1.27	0.291	0.771
治疗后	4.12 ± 1.61	4.08 ± 1.45	0.143	0.887
t值	0.331	0.241
P值	0.741	0.810
双歧杆菌
治疗前	5.57 ± 1.38	5.24 ± 1.41	1.296	0.198
治疗后	6.26 ± 1.16	6.31±1.30	0.222	0.824
t值	2.965	4.322
P值	0.004	< 0.001

Effects of simethicone on gastrointestinal hormones， intestinal floras and inflammatory process mediated by NLRP3 inflammasome in patients with irritable bowel syndrome

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 7

References 24

Related Articles 2

Recommended Articles

Metrics

Comments

项目	观察组（n = 60）	对照组（n = 60）	t值	P值
NLRP3炎性小体（pg/L）
治疗前	112.69 ± 13.85	114.57 ± 12.34	0.785	0.434
治疗后	83.20 ± 10.42	84.06 ± 10.91	0.442	0.660
t值	13.180	14.348
P值	< 0.001	< 0.001
IL-8（ng/L）
治疗前	129.83 ± 21.39	126.78 ± 20.53	0.7997	0.427
治疗后	94.41 ± 14.52	96.42 ± 15.36	0.737	0.463
t值	10.613	9.172
P值	< 0.001	< 0.001
IL-1β（ng/L）
治疗前	51.34 ± 6.75	52.64 ± 6.62	1.065	0.289
治疗后	41.76 ± 5.42	43.41 ± 6.04	1.575	0.118
t值	8.572	7.978
P值	< 0.001	< 0.001

项目	观察组（n = 60）	对照组（n = 60）	χ²值	P值
恶心呕吐	4	2
头晕头痛	2	1
便秘	1	2
口干	2	2
发生率（%）	15.00	11.67	0.288	0.591

[1]	Xin DOU,Changhui HE,Xiao MEI,Haidi PAN,Yuanxin MA,Wei. WANG. Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway [J]. The Journal of Practical Medicine, 2024, 40(15): 2177-2182.
[2]	LV Mi, ZHANG Kunli, SHI Zhongfei, ZHENG Yijun, LIU Ping, YIN Xiaolan, WANG Fengyun. . Current situation of overlap between FD and IBS based on Rome Ⅳ criteria [J]. The Journal of Practical Medicine, 2021, 37(9): 1213-1216.